Welcome to the U.S. headquarters of Novo Nordisk, a global company dedicated to diabetes care for more than 80 years. At Novo Nordisk, we feel passionately and with a sense of responsibility to be a part of the diabetes community that is working to educate people, as well as to prevent, treat, and ultimately defeat this serious disease. It's our life's work, and we'll continue to invest resources and support for those who live with or care for someone with diabetes.
Our research is highly dedicated to diabetes. We have developed the most complete range of insulin analogs, and we have designed insulin delivery systems that give patients with diabetes options for controlling their disease. Committed to changing the way people live with diabetes, we want everyone with diabetes to be in control of their lives, and we are passionate about providing support to those people battling this devastating disease.
At Novo Nordisk we're more than just a pharmaceutical company. We consider ourselves a healthcare company. We are owned by the Novo Nordisk Foundation, which is dedicated to making scientific, humanitarian, and social progress. Additionally, to improve diabetes care and increase access in developing countries, we established the World Diabetes Foundation, committing more than $225 million from 2001-2017. Finally, our organization is home to the Hagedorn Research Institute, supported by grants from the National Institutes of Health and Juvenile Diabetes Research Foundation, which conducts independent basic research toward a cure for diabetes and the Steno Diabetes Center, a World Health Organization Collaborating diabetes hospital.
But diabetes is not our only focus. We work in hemophilia and growth disorders, where we believe we can make a significant difference. Our milestones in these diseases include developing our recombinant factors and establishing the Novo Nordisk Hemophilia Foundation. For the treatment of growth disorders, we created our recombinant growth hormone with innovative delivery systems.
Our commitment to patients and our employees is reflected in our Triple Bottom Line - creating a sustainable business that is financially viable, socially responsible, and environmentally sound. Patients come first and this means working in ways that instills trust with all members of the diabetes community. In New Jersey, we have been recognized as the best employer for two of the last four years.
If you have anything to share with me, in the interest of our employees, patients, or healthcare professionals in the therapeutic areas of diabetes, hemophilia, or growth disorders, I invite you to write to me at President of Novo Nordisk.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)